AbbVie Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AbbVie Inc. on December 16, 2021. The report discloses a significant change in executive leadership effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Robert A. Michael to the role of Vice Chairman, Finance and Commercial Operations and Chief Financial Officer, effective December 16, 2021. Mr. Michael had previously served as Executive Vice President and Chief Financial Officer since October 2018.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is limited to the announcement of the executive appointment.
Key Facts for Investor Verification
- Robert A. Michael has been promoted to Vice Chairman, Finance and Commercial Operations and Chief Financial Officer.
- The appointment is effective as of December 16, 2021.
- Mr. Michael has been with the company since 1993 (via Abbott Laboratories) and has held various finance leadership roles since 2013.
- The report lists multiple classes of senior notes registered on the New York Stock Exchange, ranging from maturities in 2023 to 2031.